1/19/07 Update
The week ended with the Nasdaq Biotech Index closing virtually unchanged at a 4.00% YTD gain (vs. up 4.09% YTD at the prior Friday's close). The 31 Contest portfolios did slightly better, closing Friday with a median 2.68% YTD gain (vs. a 2.43% YTD gain at the prior Friday's close). At week's end, 19 of the 31 Contest portfolios were in the black and 9 of the 31 were beating the NBI.
Thanks to an amazing performance by the Canadian penny biotech, Inex Pharmaceuticals, my own portfolio surged into the No. 1 position, closing Friday with a 24.7% YTD gain. (As I've previously posted, perhaps foolishly, I've not yet sold any of my real life shares since I believe Inex's market cap of about US$40 million is still below the value of its IP and partnerships.) Tiley's portfolio is in second place, with a not too shabby 11.1% YTD gain.
Below is the Top Ten list on 1/19/07:
1/19/07
Rank Name Total
1 BULBA 24,653
2 TILEY 11,111
3 MANNY 9,454
4 GENE 8,589
5 STEVEL 8,404
6 WILDER 5,602
7 SCARAM 5,105
8 PRAVEEN 4,998
9 FRED 4,624
10 MOPGCW 3,929
(All corrections greatly appreciated.) |
